Metastasiertes Prostatakarzinom

Metastasiertes, hormonsensitives Adenokarzinom
der Prostata (mHSPC) Studie PSMAddition

To determine whether the therapy with 177Lu-PSMA-617 in combination with ARDT and ADT improves the radiographic progression free survival compared to the standard of care, ARDT and ADT alone, in metastatic hormone sensitive prostate cancer (mHSPC) participants that were previously minimally treated.

Ausführliche Informationen


Metastasiertes hormonsensitives Prostatakarzinom
mHSPC

Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) (AMPLITUDE)

Ausführliche Informationen


Metastasiertes kastrationsresistentes Prostatakarzinom
mCRPC

Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)

Ausführliche Informationen


Metastasiertes kastrationsresistentes Prostatakarzinom
mCRPC

Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)

Ausführliche Informationen


Metastasiertes kastrationsresistentes Prostatakarzinom
mCRPC
Monotherapie XL-092

A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors

Ausführliche Informationen


Metastasiertes kastrationsresistentes Prostatakarzinom
mCRPC
Kombination XL-092 und Immuntherapie

A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors

Ausführliche Informationen


Metastasiertes kastrationsresistentes Prostatakarzinom mCRPC

PSMAfore Studie: To determine whether the therapy with 177Lu-PSMA-617 improves the radiographic progression free survival or death compared to a change in ARDT therapy in metastatic castrate resistant prostate cancer (mCRPC) participants that were previously treated with a different ARDT and are taxane-naïve.

Ausführliche Informationen